"Through Steve's contributions over the past 11 years, Acceleron has
grown from a small, private, discovery-stage start-up to a public
company with multiple therapeutic candidates in clinical trials, the
most advanced of which is now being studied in two ongoing Phase 3
Steve joined Acceleron in
Acceleron is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases. Its pioneering research platform leverages the powerful biology behind the body's ability to rebuild and repair its own cells and tissues. This approach to drug discovery has generated four therapeutic candidates that are currently in clinical trials. The Company's lead therapeutic candidate, luspatercept, is being evaluated in Phase 3 studies for the treatment of the hematologic diseases myelodysplastic syndromes (MDS) and beta-thalassemia under a global partnership with Celgene Corp. Acceleron is also advancing clinical programs in the fields of oncology and neuromuscular diseases and has a comprehensive preclinical research effort targeting fibrotic and other serious diseases.
Senior Director, Investor Relations and Corporate Communications
News Provided by Acquire Media